The BOP-associated 5-year survival advantage almost reached significance in the subgroup of patients who responded to therapy ( 74 % vs. 56 % ; P = 0.05 ) , and did reach significance in responders who did not receive interferon maintenance therapy ( 70 % vs. 47 % ; P = 0.03 ) .
